This newsletter discusses ongoing research to develop new antiretroviral drugs for HIV disease that present less adverse effects while offering improved potency for persons living with the disease. It includes ideas on financing these costly antiretroviral treatments. The newsletter also provides a table of AIDS drugs approved by the FDA, an AIDS Drug Assistance Program restrictions map, an update on CARE Act data reporting, and major steps in the HIV life cycle. It also includes references.
|